MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
07 févr. 2023 16h01 HE
|
MediWound Ltd.
YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
03 févr. 2023 10h30 HE
|
MediWound Ltd.
YAVNE, Israel, Feb. 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
29 déc. 2022 13h46 HE
|
MediWound Ltd.
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation;...
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
23 déc. 2022 08h00 HE
|
MediWound Ltd.
Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd. ...
MediWound Strengthens European Presence of NexoBrid®
20 déc. 2022 08h00 HE
|
MediWound Ltd.
NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- MediWound...
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
19 déc. 2022 07h00 HE
|
MediWound Ltd.
MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MediWound...
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
13 déc. 2022 05h30 HE
|
MediWound Ltd.
YAVNE, Israel, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces a 1-for-7 Reverse Share Split
05 déc. 2022 16h05 HE
|
MediWound Ltd.
YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound” or the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic...
MediWound to Report Third Quarter 2022 Financial Results
03 nov. 2022 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces Formation of Strategic Advisory Board
25 oct. 2022 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...